Kabir Nath

Kabir is a senior commercial leader with more than 25 years of broad international biopharma and devices experience who has shaped strategy and delivered results in complex, challenging business environments at country, regional and global levels. He has lived and worked in the U.K., France, Spain, India, Singapore, China and the US. Kabir joined Otsuka to head the North American pharmaceutical business in March 2016, with direct responsibility for Otsuka America Pharmaceuticals, Inc., Avanir and Otsuka Canada.

Before joining Otsuka, Kabir spent 13 years in leadership roles at Bristol Myers Squibb. Most recently he was Senior Vice President, Virology, Transplant & Optimized Brands, responsible for the commercialization of a significant portfolio—including drugs for HIV, hepatitis B and hepatitis C and immunosuppression—in the USA. Previously he was Senior Vice President, Global Commercialization—Virology & Neuroscience, leading global strategy for these two disease areas. In addition he served as interim head of Emerging Markets for much of 2012. Kabir joined BMS in Singapore in 2003 as vice president for South East Asia/ Taiwan/HK and moved to Shanghai in 2005 as president of BMS China. In 2008, Kabir was appointed president, Asia Pacific Medicines, with responsibility for all commercial operations in 13 countries.

Prior to joining BMS, Kabir spent 11 years at Smith & Nephew, the medical technology company, in senior operational and strategic roles in the U.K., Europe and Asia.

Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.